Comparison between Aptus Pharma IPO and Shreyas Fabtech IPO.
Aptus Pharma IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Shreyas Fabtech IPO is a SME Bookbuilding proposed to list at NSE SME.
| Aptus Pharma IPO | Shreyas Fabtech IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | NSE SME |
| Lead Managers | Interactive Financial Services Ltd. | Gretex Corporate Services Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | Market-Hub Stock Broking Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Aptus Pharma IPO is up to ₹12.36 Cr whereas the issue size of the Shreyas Fabtech IPO is up to ₹0.00 Cr. The final issue price of Aptus Pharma IPO is ₹70.00 per share and of Shreyas Fabtech IPO is .
| Aptus Pharma IPO | Shreyas Fabtech IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹65.00 per share | |
| Issue Price (Upper) | ₹70.00 per share | |
| Issue Price (Final) | ₹70.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 2000 shares | |
| Fresh Issue Size | 17,66,000 shares | 52,83,600 shares |
| Fresh Issue Size (Amount) | up to ₹12.36 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 17,66,000 shares | 52,83,600 shares |
| Issue Size Total (Amount) | up to ₹12.36 Cr | up to ₹0.00 Cr |
Aptus Pharma IPO opens on Sep 23, 2025, while Shreyas Fabtech IPO opens on . The closing date of Aptus Pharma IPO and Shreyas Fabtech IPO is Sep 25, 2025, and , respectively.
| Aptus Pharma IPO | Shreyas Fabtech IPO | |
|---|---|---|
| Anchor Bid Date | Sep 22, 2025 | |
| Issue Open | Sep 23, 2025 | |
| Issue Close | Sep 25, 2025 | |
| Basis Of Allotment (Tentative) | Sep 26, 2025 | |
| Initiation of Refunds (Tentative) | Sep 29, 2025 | |
| Credit of Share (Tentative) | Sep 29, 2025 | |
| Listing date (Tentative) | Sep 30, 2025 | |
| Anchor Lockin End date 1 | Oct 26, 2025 | |
| Anchor Lockin End date 2 | Dec 25, 2025 |
Aptus Pharma IPO P/E ratio is 11.29, as compared to Shreyas Fabtech IPO P/E ratio of .
| Aptus Pharma IPO | Shreyas Fabtech IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Aptus Pharma Ltd.'s revenue increased by 38% and profit after tax (PAT) rose by 288% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Shreyas Fabtech Ltd.'s revenue increased by 117% and profit after tax (PAT) rose by 88% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 99.96 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 72.89 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 11.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹48.02 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 44.50% | 43.62% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 45.66% | 33.82% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.49 | 0.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 44.50% | 43.62% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Aptus Pharma IPO Retail Individual Investors (RII) are offered 6,20,000 shares while in Shreyas Fabtech IPO retail investors are offered 6,20,000 shares. Qualified Institutional Buyers (QIB) are offered 3,52,000 shares in Aptus Pharma IPO and 0 shares in Shreyas Fabtech IPO.
| Aptus Pharma IPO | Shreyas Fabtech IPO | |
|---|---|---|
| Anchor Investor Reservation | 5,28,000 shares | 0 shares |
| Market Maker Reservation | 94,000 shares | 0 shares |
| QIB | 3,52,000 shares | 0 shares |
| NII | 2,66,000 shares | 0 shares |
| RII | 6,20,000 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 17,66,000 shares | 0 shares |
Aptus Pharma IPO subscribed 22.27x in total, whereas Shreyas Fabtech IPO subscribed .
| Aptus Pharma IPO | Shreyas Fabtech IPO | |
|---|---|---|
| QIB (times) | 1.24x | |
| NII (times) | 28.75x | |
| Big NII (times) | 30.64x | |
| Small NII (times) | 24.93x | |
| RII (times) | 31.43x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 22.27x |
